Nyxoah is trading 5.03% down at $1.13 on October 16, with no clear catalyst identified. - Nyxoah closed at $1.19 on October 15, down 4.80%. - A proposed $50 million at-the-market equity offering could raise dilution concerns, but its timing and connection to today’s move are not established. - Positive 12-month study data and an FDA submission do not explain the decline; healthcare-sector strength provides no same-direction explanation.